EBPL

Summary

EBPL (EBP like, HGNC:18061) is a protein-coding gene on chromosome 13q14.2, encoding Emopamil-binding protein-like (Q9BY08). Does not possess sterol isomerase activity and does not bind sigma ligands.

Predicted to enable cholestenol delta-isomerase activity. Predicted to be involved in sterol metabolic process. Located in endoplasmic reticulum.

Source: NCBI Gene 84650 — automated summary from GO annotations (Alliance of Genome Resources).

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 41 total
• GTEx eGene: eQTL in 49 tissues, sQTL in 31 (q < 0.05)
• ChEMBL bioactivity: 2 clinical-phase molecules tested; no curated mechanism-of-action drug
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.41 (unconstrained)
• MANE Select transcript: NM_032565

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18061
Approved symbol	EBPL
Name	EBP like
Location	13q14.2
Locus type	gene with protein product
Status	Approved
Aliases	EBRP
Ensembl gene	ENSG00000123179
Ensembl biotype	protein_coding
OMIM	617335
Entrez	84650

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 11 protein_coding, 2 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

MANE Select: ENST00000242827

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 3, TSL 2: 2, TSL 3: 2

ENST00000242827, ENST00000378268, ENST00000378270, ENST00000378272, ENST00000378284, ENST00000473576, ENST00000495963, ENST00000900209, ENST00000900210, ENST00001001999, ENST00001002000, ENST00001002001, ENST00001118046, ENST00001118047, ENST00001131859

RefSeq mRNA: 2 — MANE Select: NM_032565 NM_001278636, NM_032565

CCDS: CCDS61334, CCDS9420

Canonical transcript exons

ENST00000242827 — 4 exons

Exon	Start	End
ENSE00001816161	49660674	49661208
ENSE00001827833	49691254	49691486
ENSE00003502877	49669777	49669846
ENSE00003673328	49663057	49663195

Expression profiles

Bgee: expression breadth ubiquitous, 137 present calls, max score 97.05.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 73.7289 / max 1101.6147, expressed in 1815 samples.

Highest expression (Bgee): lobe of liver, adrenal gland cortex, adrenal gland, esophagus mucosa, body of pancreas.

Genetic regulation across tissues (GTEx eQTL / sQTL)

EBPL is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 49 tissues and its splicing (sQTL) in 31 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 80 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Adipose Subcutaneous	eqtl	8.8e-85	-0.68	13:49709253:T:C
Artery Tibial	eqtl	1.6e-83	-0.70	13:49709253:T:C
Skin Sun Exposed Lower leg	eqtl	1.6e-73	-0.67	13:49691612:G:C
Whole Blood	eqtl	1.2e-68	-0.51	13:49709253:T:C
Skin Not Sun Exposed Suprapubic	eqtl	5.2e-64	-0.68	13:49691612:G:C
Nerve Tibial	eqtl	2.8e-63	-0.85	13:49731167:C:T
Esophagus Muscularis	eqtl	1.5e-58	-0.89	13:49691102:C:T
Thyroid	eqtl	3.4e-57	-0.58	13:49709253:T:C
Adipose Visceral Omentum	eqtl	7.1e-57	-0.52	13:49709253:T:C
Cells Cultured fibroblasts	eqtl	5.1e-52	-0.40	13:49692408:A:G
Artery Aorta	eqtl	1.6e-49	-0.93	13:49691102:C:T
Testis	eqtl	6.4e-48	-1.08	13:49691102:C:T
Muscle Skeletal	eqtl	1.9e-42	-0.43	13:49692408:A:G
Esophagus Gastroesophageal Junction	eqtl	4.1e-40	-1.05	13:49731167:C:T
Lung	eqtl	8.0e-39	-0.44	13:49709253:T:C
Cells EBV-transformed lymphocytes	eqtl	2.9e-38	-0.56	13:49691973:T:C
Skin Not Sun Exposed Suprapubic	sqtl	1.4e-37	+1.98	13:49775762:G:A
Colon Sigmoid	eqtl	4.1e-37	-0.97	13:49691612:G:C
Esophagus Mucosa	eqtl	1.2e-36	+0.39	13:49690044:G:A
Brain Frontal Cortex BA9	eqtl	7.2e-35	-0.75	13:49759746:G:T

FANTOM5 promoters

1 alternative TSS:

Promoter ID	TPM avg	Samples expressed
137325	73.7289	1815

Top tissues by expression

showing 100 of 137 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	97.05	gold quality
left adrenal gland cortex	UBERON:0035825	96.25	gold quality
left adrenal gland	UBERON:0001234	96.02	gold quality
esophagus mucosa	UBERON:0002469	95.98	gold quality
right adrenal gland	UBERON:0001233	95.86	gold quality
right adrenal gland cortex	UBERON:0035827	95.65	gold quality
body of pancreas	UBERON:0001150	95.55	gold quality
vagina	UBERON:0000996	95.45	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	95.24	gold quality
liver	UBERON:0002107	95.11	gold quality
lower esophagus mucosa	UBERON:0035834	94.88	gold quality
adrenal gland	UBERON:0002369	94.59	gold quality
ectocervix	UBERON:0012249	94.47	gold quality
skin of abdomen	UBERON:0001416	94.24	gold quality
mucosa of transverse colon	UBERON:0004991	94.13	gold quality
left ovary	UBERON:0002119	93.97	gold quality
pancreas	UBERON:0001264	93.78	gold quality
ovary	UBERON:0000992	93.75	gold quality
zone of skin	UBERON:0000014	93.57	gold quality
endocervix	UBERON:0000458	93.39	gold quality
right ovary	UBERON:0002118	93.34	gold quality
skin of leg	UBERON:0001511	93.17	gold quality
body of stomach	UBERON:0001161	92.72	gold quality
esophagus	UBERON:0001043	92.71	gold quality
uterine cervix	UBERON:0000002	92.51	gold quality
fallopian tube	UBERON:0003889	92.27	gold quality
left uterine tube	UBERON:0001303	92.08	gold quality
fundus of stomach	UBERON:0001160	92.05	gold quality
endometrium	UBERON:0001295	91.99	gold quality
minor salivary gland	UBERON:0001830	91.84	gold quality
saliva-secreting gland	UBERON:0001044	91.76	gold quality
prostate gland	UBERON:0002367	91.47	gold quality
transverse colon	UBERON:0001157	91.25	gold quality
rectum	UBERON:0001052	91.24	gold quality
embryo	UBERON:0000922	91.19	gold quality
ganglionic eminence	UBERON:0004023	91.19	gold quality
stomach	UBERON:0000945	91.17	gold quality
body of uterus	UBERON:0009853	91.17	gold quality
myometrium	UBERON:0001296	91.04	gold quality
tibial nerve	UBERON:0001323	90.95	gold quality
ventricular zone	UBERON:0003053	90.93	gold quality
upper lobe of left lung	UBERON:0008952	90.93	gold quality
islet of Langerhans	UBERON:0000006	90.92	gold quality
adrenal tissue	UBERON:0018303	90.59	gold quality
cortical plate	UBERON:0005343	90.55	gold quality
thoracic mammary gland	UBERON:0005200	90.39	gold quality
lung	UBERON:0002048	90.20	gold quality
hypothalamus	UBERON:0001898	90.18	gold quality
omental fat pad	UBERON:0010414	90.12	gold quality
colon	UBERON:0001155	90.11	gold quality
urinary bladder	UBERON:0001255	90.08	gold quality
muscle layer of sigmoid colon	UBERON:0035805	89.99	gold quality
descending thoracic aorta	UBERON:0002345	89.88	gold quality
right lobe of thyroid gland	UBERON:0001119	89.84	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	89.74	gold quality
ascending aorta	UBERON:0001496	89.68	gold quality
thoracic aorta	UBERON:0001515	89.67	gold quality
cortex of kidney	UBERON:0001225	89.56	gold quality
left coronary artery	UBERON:0001626	89.46	gold quality
right lung	UBERON:0002167	89.39	gold quality
lower esophagus	UBERON:0013473	89.27	gold quality
lower esophagus muscularis layer	UBERON:0035833	89.24	gold quality
left lobe of thyroid gland	UBERON:0001120	89.04	gold quality
thyroid gland	UBERON:0002046	89.03	gold quality
intestine	UBERON:0000160	89.00	gold quality
stromal cell of endometrium	CL:0002255	88.98	gold quality
adipose tissue	UBERON:0001013	88.95	gold quality
smooth muscle tissue	UBERON:0001135	88.92	gold quality
right uterine tube	UBERON:0001302	88.57	gold quality
placenta	UBERON:0001987	88.55	gold quality
tibial artery	UBERON:0007610	88.50	gold quality
popliteal artery	UBERON:0002250	88.48	gold quality
right coronary artery	UBERON:0001625	88.47	gold quality
material anatomical entity	UBERON:0000465	88.44	gold quality
multicellular organism	UBERON:0000468	88.44	gold quality
anatomical system	UBERON:0000467	88.43	gold quality
monocyte	CL:0000576	88.33	gold quality
tonsil	UBERON:0002372	88.32	gold quality
leukocyte	CL:0000738	88.25	gold quality
metanephros cortex	UBERON:0010533	88.18	gold quality
calcaneal tendon	UBERON:0003701	88.17	gold quality
subcutaneous adipose tissue	UBERON:0002190	88.11	gold quality
amygdala	UBERON:0001876	87.86	gold quality
temporal lobe	UBERON:0001871	87.75	gold quality
substantia nigra	UBERON:0002038	87.59	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.54	gold quality
anterior cingulate cortex	UBERON:0009835	87.40	gold quality
mucosa of stomach	UBERON:0001199	87.39	gold quality
spleen	UBERON:0002106	86.74	gold quality
adult mammalian kidney	UBERON:0000082	86.73	gold quality
Ammon’s horn	UBERON:0001954	86.71	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	86.69	gold quality
kidney	UBERON:0002113	86.58	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	86.55	gold quality
Brodmann (1909) area 9	UBERON:0013540	86.25	gold quality
bone marrow	UBERON:0002371	86.24	gold quality
duodenum	UBERON:0002114	86.17	gold quality
small intestine Peyer’s patch	UBERON:0003454	86.12	gold quality
lymph node	UBERON:0000029	86.07	gold quality
small intestine	UBERON:0002108	85.96	gold quality

Single-cell (SCXA)

Detected in 12 experiment(s), a significant marker in 9.

Experiment	Marker?	Max mean expression
E-MTAB-5061	yes	402.54
E-HCAD-4	yes	85.30
E-CURD-114	yes	61.81
E-GEOD-125970	yes	45.81
E-MTAB-10042	yes	13.76
E-HCAD-1	yes	13.13
E-MTAB-6701	yes	11.70
E-CURD-112	yes	8.61
E-HCAD-6	no	30.13
E-GEOD-81608	no	8.15
E-ENAD-27	no	4.27
E-ANND-3	no	0.00

HPA expression

RNA tissue specificity: Tissue enhanced

showing 60 of 78 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Liver	tissue	92.8	high
Vagina	tissue	37.6	medium
Esophagus	tissue	28.6	high
Ovary	tissue	24.1	not detected
Pancreas	tissue	22.2	high
Breast	tissue	21.7	medium
Adrenal gland	tissue	21.4	medium
Salivary gland	tissue	20.7	high
Skin 1	tissue	20.3	medium
Colon	tissue	18.9	medium
Bone marrow	tissue	18.7	low
Fallopian tube	tissue	17.5	high
Prostate	tissue	17.0	low
Cervix	tissue	15.9	medium
Rectum	tissue	15.2	medium
Endometrium 1	tissue	14.3	low
Thyroid gland	tissue	14.2	not detected
Urinary bladder	tissue	13.4	high
Lung	tissue	13.3	medium
Duodenum	tissue	13.3	high
Choroid plexus	tissue	12.9
Seminal vesicle	tissue	12.7	medium
Smooth muscle	tissue	12.4	not detected
Stomach 1	tissue	12.1	high
Locus coeruleus	tissue	11.7
Appendix	tissue	11.3	medium
Small intestine	tissue	11.0	medium
Placenta	tissue	10.5	not detected
Gallbladder	tissue	10.3	low
Tonsil	tissue	10.3	medium
Lymph node	tissue	10.1	not detected
Adipose tissue	tissue	10.0	not detected
Parathyroid gland	tissue	9.8	not detected
Thymus	tissue	9.6
Postcentral gyrus	tissue	9.1
Hippocampus	tissue	8.9	not detected
Spinal cord	tissue	8.8
Kidney	tissue	8.5	not detected
Corpus callosum	tissue	7.8
Nucleus accumbens	tissue	7.5
Testis	tissue	7.4	medium
Pituitary gland	tissue	7.2
Spleen	tissue	7.2	not detected
Medulla oblongata	tissue	7.1
Midbrain	tissue	6.5
Epididymis	tissue	6.2	medium
Hippocampal formation	tissue	6.0
Substantia nigra	tissue	5.8
Thalamus	tissue	5.7
Periaqueductal gray	tissue	5.7
Cerebral cortex	tissue	5.5	not detected
Somatosensory cortex	tissue	5.5
Superior colliculi	tissue	5.4
Pons	tissue	5.1
Putamen	tissue	4.8
Entorhinal cortex	tissue	4.8
Occipital cortex	tissue	4.7
Prefrontal cortex	tissue	4.6
Amygdala	tissue	4.5
Ventral forebrain	tissue	4.5

Brain sub-regions (HPA Brain Atlas): detected in 191; highest nTPM — Dorsal funiculus (white matter) (15.0), Blood vessel (14.3), Cervical spinal cord, ventral horn (13.6), Cervical spinal cord, dorsal horn (13.4), Lateral funiculus (white matter) (13.4).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting EBPL by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 34 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-613	99.91	71.50	1710
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-4446-5P	99.72	69.19	2544
HSA-MIR-7154-5P	99.69	70.52	1900
HSA-MIR-7156-5P	99.64	68.81	1369
HSA-MIR-510-3P	99.54	70.06	2965
HSA-MIR-6833-5P	99.50	68.93	1161
HSA-MIR-4273	99.45	67.93	1206
HSA-MIR-1206	99.30	69.32	1016
HSA-MIR-6739-3P	99.22	68.84	1843
HSA-MIR-10399-5P	99.17	69.87	2610
HSA-MIR-6504-3P	99.17	69.31	2891
HSA-MIR-3926	98.95	69.26	1438
HSA-MIR-8060	98.61	66.93	1187
HSA-MIR-4463	98.56	66.05	1071
HSA-MIR-548S	98.50	67.17	1213
HSA-MIR-2117	98.48	67.97	1307
HSA-MIR-6883-3P	97.97	67.35	643
HSA-MIR-3190-3P	97.61	66.95	1406
HSA-MIR-4670-3P	97.37	68.35	1378
HSA-MIR-3194-5P	96.80	64.90	1027
HSA-MIR-4491	96.53	66.20	935

Functional genomics

gnomAD constraint: pLI 6.17e-09, LOEUF 1.41, missense Z 0.0541 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000242827 splits into 2 regions with different missense tolerance; 0 are missense-constrained. Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
13:49,660,971–49,663,064	49 / 94.1	0.52	no
13:49,663,065–49,691,424	170 / 167.0	1.02	no

Literature-anchored findings (GeneRIF, showing 1)

• encoded by four exons on human chromosome 13q14.2 covering 30.7 kb, and a partially processed EBPL pseudogene was found on 16q21; expressed ubiquitously and most abundant in liver, lung and kidney (PMID:12760743)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ebpl	ENSDARG00000036636
mus_musculus	Ebpl	ENSMUSG00000021928
rattus_norvegicus	Ebpl	ENSRNOG00000014659

Paralogs (1): EBP (ENSG00000147155)

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Ailanthus altissimus	A0A9Y1LNE1	75.1%	Diamond
Cavia porcellus	Q60490	74.0%	Diamond
Arabidopsis thaliana	O48962	60.3%	Diamond
Oryza sativa Japonica Group	Q9FTZ2	60.3%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
KPNA3	protein-coding	3839
ARL11	protein-coding	115761
RCBTB1	protein-coding	55213

Protein

Protein identifiers

Emopamil-binding protein-like — Q9BY08 (reviewed: Q9BY08)

Alternative names: Emopamil-binding-related protein

All UniProt accessions (3): A0A0A0MRV2, Q6GPH7, Q9BY08

UniProt curated annotations — full annotation on UniProt →

Function. Does not possess sterol isomerase activity and does not bind sigma ligands.

Subunit / interactions. Homodimer.

Subcellular location. Endoplasmic reticulum membrane.

Tissue specificity. Widely expressed with highest levels in liver, lung and kidney.

Similarity. Belongs to the EBP family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q9BY08-1	1	yes
Q9BY08-2	2
Q9BY08-3	3
Q9BY08-4	4
Q9BY08-5	5

RefSeq proteins (2): NP_001265565, NP_115954* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007905	EBP	Family
IPR033118	EXPERA	Domain

Pfam: PF05241

UniProt features (16 total): splice variant 9, transmembrane region 4, chain 1, sequence conflict 1, domain 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BY08-F1	94.06	0.92

Human Protein Atlas

Protein class: Predicted membrane proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): endoplasmic reticulum

Antibody reliability (HPA): IH enhanced · IF supported

Function

Pathways and Gene Ontology

Reactome pathways

0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

MSigDB gene sets: 122 (showing top): HORIUCHI_WTAP_TARGETS_DN, CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_LIPID_METABOLIC_PROCESS, JAATINEN_HEMATOPOIETIC_STEM_CELL_UP, CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_UP, KONDO_PROSTATE_CANCER_HCP_WITH_H3K27ME3, GOBP_STEROID_METABOLIC_PROCESS, chr13q14, OSMAN_BLADDER_CANCER_DN, GOCC_NUCLEAR_OUTER_MEMBRANE_ENDOPLASMIC_RETICULUM_MEMBRANE_NETWORK, GOCC_ORGANELLE_SUBCOMPARTMENT, GOMF_INTRAMOLECULAR_OXIDOREDUCTASE_ACTIVITY_TRANSPOSING_C_C_BONDS, GOMF_INTRAMOLECULAR_OXIDOREDUCTASE_ACTIVITY, GOMF_ISOMERASE_ACTIVITY

GO Biological Process (1): sterol metabolic process (GO:0016125)

GO Molecular Function (1): cholestenol delta-isomerase activity (GO:0047750)

GO Cellular Component (3): endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020)

GO top-level categories

9 GO namespaces:

Category	Terms
steroid metabolic process	1
intramolecular oxidoreductase activity, transposing C=C bonds	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cellular anatomical structure	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 1 of 5 annotations. The rest are phylogenetic / computational / electronic (IEA).

1 experimentally-supported GO terms:

GO term	NS	Evidence
endoplasmic reticulum	CC	direct assay

Protein interactions and networks

STRING

showing 15 of 590 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EBPL	SPRYD7	Q5W111	598
EBPL	KPNA3	O00505	567
EBPL	RCBTB1	Q8NDN9	552
EBPL	DLEU7	Q6UYE1	521
EBPL	WDR13	Q9H1Z4	486
EBPL	CAB39L	Q9H9S4	486
EBPL	MOSPD1	Q9UJG1	476
EBPL	TSR3	Q9UJK0	473
EBPL	CDADC1	Q9BWV3	472
EBPL	SPMIP7	A4D263	469
EBPL	DHCR7	Q9UBM7	464
EBPL	TBC1D25	Q3MII6	463
EBPL	ITM2B	Q9Y287	458
EBPL	TMEM158	Q8WZ71	447
EBPL	NUFIP2	Q7Z417	439

IntAct

Human interaction partners of EBPL in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

2 partners by confidence:

Partner	Interaction type	MIscore	Records
HNRNPU	physical association	0.400	1
DEPDC1B	physical association	0.370	1

BioGRID (2 interactions; top human partners by supporting records): DEPDC1B (Two-hybrid), NLGN3 (Two-hybrid)

Disease & clinical

Genetic variants

Variant evidence for EBPL: 41 ClinVar records (0 pathogenic / likely pathogenic); 4 GWAS associations.

ClinVar

41 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	30
Likely benign	3
Benign	0

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 25 predictions of 312):

Position(s)	Effect	Δscore	Sites
13:49691253	donor_loss	1.0000
13:49661209–49661210	acceptor_loss	0.9900	6
13:49663055–49663056	donor_loss	0.9900	5
13:49663196	acceptor_gain	0.9900
13:49663196–49663197	acceptor_loss	0.9900	5
13:49691252–49691253	donor_loss	0.9900	2
13:49661212	acceptor_gain	0.9800
13:49663055	donor_loss	0.9800
13:49691252–49691253	donor_loss	0.9700	2
13:49672339	donor_gain	0.9400

AlphaMissense

188 missense substitutions predicted likely pathogenic (of 1,309 scored), across 79 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
D88	7	0.763	0.821
W91	6	0.784	0.867
F61	6	0.781	0.938
W46	6	0.742	0.899
W81	6	0.726	0.859
R90	5	0.774	0.818
F146	5	0.774	0.899
W176	5	0.755	0.804
E138	5	0.717	0.792
Y84	5	0.692	0.767
M144	5	0.636	0.655
C135	4	0.784	0.845
E58	4	0.762	0.854
E102	4	0.745	0.794
H54	4	0.736	0.788
G110	4	0.677	0.729
F129	3	0.791	0.791
S154	3	0.771	0.771
Q131	3	0.757	0.833
K82	3	0.723	0.791

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

2 prognostic cancer types:

Cancer	Prognostic	p-value
Pancreatic Adenocarcinoma (validation)	unfavorable	5.31e-05
Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA)	unfavorable	0.000473

Disease associations

OMIM: gene MIM:617335 | disease phenotypes:

GWAS associations

4 associations:

Study	Trait	p-value
GCST010002_238	Refractive error	1e-36
GCST90020028_1169	Hip circumference adjusted for BMI	1e-14
GCST012227_153	Hip circumference adjusted for BMI	2e-12
GCST007052_4	Lipoprotein (a) levels	1e-6

EFO canonical traits (from GWAS)

2 canonical traits:

EFO ID	Trait name
EFO:0006925	lipoprotein A measurement
EFO:0008039	BMI-adjusted hip circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2311238 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 193,477 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

2 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL83	TAMOXIFEN	4	173,287
CHEMBL422	TRIFLUOPERAZINE	4	20,190

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

132 measured of 132 human assays (132 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
CHEMBL2314420	KI	1.7 nM
7-[2-[(5-Chloro-6-cyclohexyl-3- pyridyl)oxy]ethyl]-26-thia-7- azaspiro[3.5]nonane 2,2-dioxide	KI	1.96 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-((1-(4- (Trifluoromethyl)phenoxy) cyclobutyl)methyl)-2-thia-7- azaspiro[3.5]nonane 2,2-dioxide	KI	3.7 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
(2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine	KI	5 nM
(R)-6-(3-(4-cyclobutylphenyl)-2- methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide (S)-6-(3-(4-cyclobutylphenyl)-2- methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide	KI	5.14 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-(2-((6-((trans)-4- (Trifluoromethyl)cyclohexyl) pyridin-3-yl)oxy)ethyl)-2-thia-7- azaspiro[3.5]nonane 2,2-dioxide	KI	5.72 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
(R)-6-(3-(4-cyclobutylphenyl)-2- methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide (S)-6-(3-(4-cyclobutylphenyl)-2- methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide	KI	6.54 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-(2-(4- (Trifluoromethoxy)phenoxy)ethyl)- 2-thia-7-azaspiro[3.5]nonane 2,2-dioxide	KI	6.54 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-(2,2-Dimethyl-3-(4- (trifluoromethyl)phenyl)propyl)- 2-thia-7-azaspiro[3.5]nonane- 2,2-dioxide	KI	7.23 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
(S)-6-(2-Methyl-3-(4- (trifluoromethoxy)phenyl)propyl)- 2-thia-6-azaspiro[3.4]octane 2,2-dioxide (R)-6-(2-Methyl-3-(4- (trifluoromethoxy)phenyl)propyl)- 2-thia-6-azaspiro[3.4]octane 2,2-dioxide	KI	7.27 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-(2-(4-Chloro-3- fluorophenoxy)-2- methylpropyl)-2-thia-7- azaspiro[3.5]nonane 2,2-dioxide	KI	7.31 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-(2-(3-Fluoro-4- (trifluoromethyl)phenoxy)ethyl)- 2-thia-7-azaspiro[3.5]nonane 2,2-dioxide	KI	7.95 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
cid_2913535	KI	8 nM
6-3-(4-(2,2- Dimethylcyclopropyl)phenyl)-2- methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide	KI	8.31 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-2-Methyl-3-(4-(tert- pentyl)phenyl)propyl)-2-thia-7- azaspiro[4.4]nonane 2,2-dioxide	KI	8.38 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-(2-Methyl-3-(4-(tert- pentyl)phenyl)propyl)-2-thia-7- azaspiro[3.5]nonane 2,2-dioxide	KI	8.44 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
6-(2-Methyl-3-(4-(1- methylcyclopropyl)phenyl)propyl)- 2-thia-6-azaspiro[3.4]octane 2,2-dioxide	KI	8.57 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-(2-((6-((cis)-4- (trifluoromethyl)cyclohexyl) pyridin-3-yl)oxy)ethyl)-2-thia-7- azaspiro[3.5]nonane 2,2-dioxide	KI	8.97 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-(2-(4- (Trifluoromethyl)phenoxy)ethyl)- 2-thia-7-azaspiro[3.5]nonane 2,2-dioxide	KI	9.29 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
6-((S)-3-(3-Chloro-4-((1s,4R)-4- hydroxy-4- (trifluoromethyl)cyclohexyl)phenyl)- 2-methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide	KI	9.31 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
(S)-6-(3-(3-Chloro-4-(4,4- difluorocyclohexyl)phenyl)-2- methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide (R)-6-(3-(3-Chloro-4-(4,4- difluorocyclohexyl)phenyl)-2- methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide	KI	9.43 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
6-(3-(4- (Trifluoromethyl)phenyl)propyl)- 2-thia-6-azaspiro[3.4]octane- 2,2-dioxide	KI	9.45 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
6-(3-(4-Cyclopropylphenyl)-2- methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide	KI	9.72 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
(R)-7-(2-(4- (trifluoromethyl)phenoxy)propyl)- 2-thia-7-azaspiro[3.5]nonane 2,2-dioxide	KI	9.8 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
(S)-6-(3-(3-Chloro-4-(4,4- difluorocyclohexyl)phenyl)-2- methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide (R)-6-(3-(3-Chloro-4-(4,4- difluorocyclohexyl)phenyl)-2- methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide	KI	9.86 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
(S)-7-(2-Methyl-3-(4- (trifluoromethyl)phenyl)propyl)- 2-thia-7-azaspiro[3.5]nonane 2,2-dioxide	KI	9.98 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-(2-(3,4- Difluorophenoxy)ethyl)-2-thia- 7-azaspiro[3.5]nonane 2,2- dioxide	KI	10 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
(S)-7-(2-(3,4- Difluorophenoxy)propyl)-2-thia- 7-azaspiro[3.5]nonane 2,2- dioxide	KI	10 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
(R)-7-(3-(3,4-difluorophenyl)-2- methylpropyl)-2-thia-7- azaspiro[3.5]nonane 2,2-dioxide	KI	10.1 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
6-((S)-3-(3-Chloro-4-((1s,4R)-4- hydroxy-4- (trifluoromethyl)cyclohexyl)phenyl)- 2-methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide	KI	10.5 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
(S)-6-(2-Methyl-3-(4- (trifluoromethoxy)phenyl)propyl)- 2-thia-6-azaspiro[3.4]octane 2,2-dioxide (R)-6-(2-Methyl-3-(4- (trifluoromethoxy)phenyl)propyl)- 2-thia-6-azaspiro[3.4]octane 2,2-dioxide	KI	10.5 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
(R)-7-(2-(3,4- difluorophenoxy)propyl)-2-thia- 7-azaspiro[3.5]nonane 2,2- dioxide	KI	10.6 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-(2-((6-Cyclohexyl-5- (trifluoromethyl)pyridin-3- yl)oxy)ethyl)-2-thia-7- azaspiro[3.5]nonane 2,2-dioxide	KI	10.7 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
6-((R)-3-(3-Chloro-4-((1r,4R)-4- hydroxy-4- methylcyclohexyl)phenyl)-2- methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide 6-((S)-3-(3-chloro-4-((1r,4S)-4- hydroxy-4- methylcyclohexyl)phenyl)-2- methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide 6-((S)-3-(3-Chloro-4-((1r,4S)-4- hydroxy-4- methylcyclohexyl)phenyl)-2- methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide	KI	11 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
6-((R)-3-(3-Chloro-4-((1r,4R)-4- hydroxy-4- methylcyclohexyl)phenyl)-2- methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide 6-((S)-3-(3-chloro-4-((1r,4S)-4- hydroxy-4- methylcyclohexyl)phenyl)-2- methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide 6-((S)-3-(3-Chloro-4-((1r,4S)-4- hydroxy-4- methylcyclohexyl)phenyl)-2- methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide	KI	11.9 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-(2-(4-Fluoro-3- (trifluoromethyl)phenoxy)-2- methylpropyl)-2-thia-7- azaspiro[3.5]nonane 2,2-dioxide	KI	11.9 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-(3-(4- (Trifluoromethoxy)phenyl)propyl)- 2-thia-7-azaspiro[3.5]nonane 2,2-dioxide	KI	12 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-(2-((5-Chloro-6-((trans)-4- (trifluoromethyl)cyclohexyl) pyridin-3-yl)oxy)ethyl)-2-thia-7- azaspiro[3.5]nonane 2,2-dioxide	KI	12.2 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
2-[(2S)-2-methyl-3-[4-(trifluoromethyl)phenyl]propyl]-7lambda6-thia-2-azaspiro[3.5]nonane 7,7-dioxide	KI	12.7 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-(2-(3-Fluoro-4- (trifluoromethyl)phenoxy)-2- methylpropyl)-2-thia-7- azaspiro[3.5]nonane 2,2-dioxide	KI	12.8 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
6-(4-(4-(tert- Pentyl)phenyl)butan-2-yl)-2- thia-6-azaspiro[3.4]octane 2,2- dioxide	KI	12.9 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
2-(2-(4- (Trifluoromethyl)phenoxy)ethyl)- 7-thia-2-azaspiro[3.5]nonane 7,7-dioxide	KI	13 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-[2-[[5-Chloro-6- (trifluoromethyl)-3- pyridyl]oxy]ethyl]-26-thia-7- azaspiro[3.5]nonane 2,2-dioxide	KI	13.1 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-(2-(4-Chloro-3- fluorophenoxy)ethyl)-2-thia-7- azaspiro[3.5]nonane 2,2-dioxide	KI	13.2 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-(2-Methyl-2-(3- (trifluoromethyl)phenoxy)propyl)- 2-thia-7-azaspiro[3.5]nonane 2,2-dioxide	KI	13.2 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
(R)-6-(2-(4- (Trifluoromethyl)phenoxy)propyl)- 2-thia-6-azaspiro[3.4]octane 2,2-dioxide (S)-6-(2-(4- (Trifluoromethyl)phenoxy)propyl)- 2-thia-6-azaspiro[3.4]octane 2,2-dioxide	KI	13.5 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
7-(2-(3,4-Difluorophenoxy)-2- methylpropyl)-2-thia-7- azaspiro[3.5]nonane 2,2-dioxide	KI	13.9 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
2-(2-Methyl-2-(4- (trifluoromethyl)phenoxy)propyl)- 7-thia-2-azaspiro[3.5]nonane 7,7-dioxide	KI	13.9 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
2-[(2R)-2-methyl-3-[4-(trifluoromethyl)phenyl]propyl]-7lambda6-thia-2-azaspiro[3.5]nonane 7,7-dioxide	KI	13.9 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
(S)-6-(3-(1-Isopropyl-3- (trifluoromethyl)-1H-pyrazol-5- yl)-2-methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide (R)-6-(3-(1-isopropyl-3- (trifluoromethyl)-1H-pyrazol-5- yl)-2-methylpropyl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide	KI	14 nM	US-20240400579: SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.76	Ki	1.72	nM	CHEMBL2314420
8.55	Ki	2.8	nM	TAMOXIFEN
8.41	Ki	3.9	nM	TRIFLUOPERAZINE
5.85	Ki	1400	nM	[18F]FLUSPIDINE

PubChem BioAssay actives

4 with measured affinity, of 4 total; 4 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
1-[2-(3-hydroperoxy-4-methoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine	723649: Binding affinity to emopamil binding protein (unknown origin)	ki	0.0017	uM
Tamoxifen	723649: Binding affinity to emopamil binding protein (unknown origin)	ki	0.0028	uM
Trifluoperazine	723649: Binding affinity to emopamil binding protein (unknown origin)	ki	0.0039	uM
1’-benzyl-1-(2-(17F)fluoroethyl)spiro[1H-2-benzofuran-3,4’-piperidine]	723649: Binding affinity to emopamil binding protein (unknown origin)	ki	1.4000	uM

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	3
Air Pollutants	decreases expression, increases abundance	2
Arsenic	affects cotreatment, increases abundance, increases expression	2
Benzo(a)pyrene	decreases expression, decreases methylation	2
Particulate Matter	increases abundance, decreases expression	2
aristolochic acid I	decreases expression	1
triphenyl phosphate	affects expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	increases expression	1
K 7174	decreases expression	1
abrine	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Temozolomide	increases expression	1
Acetaminophen	decreases expression	1
Cisplatin	decreases expression	1
Estradiol	affects cotreatment, decreases expression	1
Formaldehyde	decreases expression	1
Gallic Acid	decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1
Urethane	decreases expression	1
Valproic Acid	decreases expression	1
Sodium Selenite	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2320419	Binding	Binding affinity to emopamil binding protein (unknown origin)	Synthesis and biological evaluation of ¹⁸F labeled fluoro-oligo-ethoxylated 4-benzylpiperazine derivatives for sigma-1 receptor imaging. — *Bioorg Med Chem*

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for EBPL across ~30M SureChEMBL compounds — explore on Sugi Predict.